MARLBOROUGH, Mass. and
NEW YORK, Jan. 28, 2016 /PRNewswire/ -- Boston
Scientific Corporation (NYSE: BSX) and Accenture (NYSE: ACN) have
developed a cloud-based, data-driven digital health solution for
hospitals that is designed to help improve patient outcomes and
reduce costs to treat patients with chronic cardiovascular
diseases.
The solution, known as ADVANTICS™ Care Pathway Transformation,
is designed to enable providers to make more proactive and informed
decisions based on insights into the patient population, ultimately
improving the care a patient experiences from hospital stay through
post-discharge care and in-home support.
The Care Pathway Transformation solution uses the Accenture
analytics insights platform, which provides actionable insights
into care coordination and patient population health patterns,
revealing opportunities to improve their consistency and
efficiency. The solution will focus on three key measurements:
- Pathway Analytics: how a patient moves through the
hospital system, how long each step takes and whether a patient can
be better served by a more efficient system;
- Care Management: how patients are diagnosed, treated and
monitored, by whom and how often, as well as their ongoing vital
signs and risk analysis; and
- Patient Engagement: how patients are educated, monitored
and receive communication during their hospitalization and after
discharge.
The solution has been tailored for insight into patients with
heart failure, but the companies plan to expand it to additional
disease states.
In developing this solution, both companies worked with two of
the largest hospitals in Scandinavia, Karolinska University
Hospital in Sweden and Tampere
Heart Hospital in Finland, to
assess the current state of care delivery for heart failure
patients and identify opportunities for improvement at each
hospital. Heart failure has been identified as one of the
costliest disease states to manage—resulting in about two percent
of healthcare spending and accounting for an average 11-day
hospital stay in Europei.
"The collaboration with Boston Scientific and Accenture exposed
significant opportunities to increase provider collaboration and
improve the quality of care that patients experience when coming to
our hospital," said Dr. Kari
Niemelä, chief executive officer, Tampere Heart Hospital.
"For example, we identified a 25 percent unnecessary heart failure
readmissions rate, and therefore a definite need for better care
coordination, supported by modern technology and processes that can
decrease overall costs."
"Boston Scientific and Accenture designed this digital health
platform to help providers standardize care, reduce overall length
of stay and lower readmission rates," said Mike Mahoney, president and chief executive
officer, Boston Scientific. "The Care Pathway Transformation
solution is designed to support healthcare professionals and
patients to have more informed relationships, leading to better
health outcomes and lower costs for health systems. Together, we
are addressing an acute need for some of the most costly chronic
conditions."
Anne O'Riordan, senior managing
director at Accenture Life Sciences, said, "Socio-economic changes
are driving the market to move to value-based care, and new
data-driven care transformation services are a great enabler of
delivering high-quality healthcare at the right cost. Working
together with Boston Scientific, we are able to bring to market
digital capabilities and analytics-driven insights that focus on
improving patient and economic outcomes."
Boston Scientific and Accenture initially plan to make the Care
Pathway Transformation solution available to hospitals in the
United Kingdom and Scandinavia and
expect to pilot projects throughout Europe and the
United States soon.
About Boston Scientific
Boston Scientific transforms
lives through innovative medical solutions that improve the health
of patients around the world. As a global medical technology
leader for more than 35 years, we advance science for life by
providing a broad range of high performance solutions that address
unmet patient needs and reduce the cost of healthcare. For
more information, visit www.bostonscientific.com and connect on
Twitter and Facebook.
About Accenture
Accenture is a leading global
professional services company, providing a broad range of services
and solutions in strategy, consulting, digital, technology and
operations. Combining unmatched experience and specialized skills
across more than 40 industries and all business functions –
underpinned by the world's largest delivery network – Accenture
works at the intersection of business and technology to help
clients improve their performance and create sustainable value for
their stakeholders. With more than 373,000 people serving clients
in more than 120 countries, Accenture drives innovation to improve
the way the world works and lives. Visit us at
www.accenture.com.
Cautionary Statement Regarding Forward-Looking
Statements
This press release contains forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933 and Section 21E of the Securities Exchange Act of 1934.
Forward-looking statements may be identified by words like
"anticipate," "expect," "project," "believe," "plan," "estimate,"
"intend" and similar words. These forward-looking statements are
based on our beliefs, assumptions and estimates using information
available to us at the time and are not intended to be guarantees
of future events or performance.These forward-looking statements
include, among other things, statements regarding the Care Pathway
Transformation solution and its impact. If our underlying
assumptions turn out to be incorrect, or if certain risks or
uncertainties materialize, actual results could vary materially
from the expectations and projections expressed or implied by our
forward-looking statements. These factors, in some cases, have
affected and in the future (together with other factors) could
affect our ability to implement our business strategy and may cause
actual results to differ materially from those contemplated by the
statements expressed in this press release. As a result, readers
are cautioned not to place undue reliance on any of our
forward-looking statements.
Factors that may cause such differences include, among other
things: future economic, competitive, reimbursement and regulatory
conditions; new product introductions; demographic trends;
intellectual property; litigation; financial market conditions; and
future business decisions made by us and our competitors. All
of these factors are difficult or impossible to predict accurately
and many of them are beyond our control. For a further list
and description of these and other important risks and
uncertainties that may affect our future operations, see Part I,
Item 1A – Risk Factors in our most recent Annual Report on Form
10-K filed with the Securities and Exchange Commission, which we
may update in Part II, Item 1A – Risk Factors in Quarterly Reports
on Form 10-Q we have filed or will file hereafter. We
disclaim any intention or obligation to publicly update or revise
any forward-looking statements to reflect any change in our
expectations or in events, conditions or circumstances on which
those expectations may be based, or that may affect the likelihood
that actual results will differ from those contained in the
forward-looking statements.This cautionary statement is applicable
to all forward-looking statements contained in this document.
CONTACTS:
U.S. Media: Tom Keppeler
Boston Scientific Corporation
508-683-6585 (office)
thomas.keppeler@bsci.com
Cam Granstra
312-693-5992 (office)
Media/Industry Analyst Relations
Accenture
cameria.l.granstra@accenture.com
European Media: Simonetta
Balbi
39 010 6060281 (office)
Boston Scientific Corporation
Simonetta.Balbi@bsci.com
Investors: Susie Lisa, CFA
508-683-5565 (office)
Boston Scientific Corporation
investor_relations@bsci.com
i Frieder Braunschweig, Martin R. Cowie, Angelo
Auricchio. "What are the costs of heart failure?"
Europace May 2011, 13 (suppl 2)
ii13-ii17; DOI: 10.1093/europace/eur081
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/boston-scientific-and-accenture-develop-data-driven-digital-health-solution-to-help-improve-patient-outcomes-and-reduce-cost-of-treating-chronic-cardiovascular-conditions-300211013.html
SOURCE Boston Scientific Corporation